|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reviews |
1 Laboratory of Pediatrics and Neurology and2 Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
aAddress correspondence to this author at: Laboratory of Pediatrics and Neurology (830), Institute of Neurology, Radboud University Nijmegen Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands. Fax 31-24-3540297; e-mail r.wevers{at}cukz.umcn.nl.
Background: Genetic diseases that affect the biosynthesis of protein O-glycans are a rapidly growing group of disorders. Because this group of disorders does not have a collective name, it is difficult to get an overview of O-glycosylation in relation to human health and disease. Many patients with an unsolved defect in N-glycosylation are found to have an abnormal O-glycosylation as well. It is becoming increasingly evident that the primary defect of these disorders is not necessarily localized in one of the glycan-specific transferases, but can likewise be found in the biosynthesis of nucleotide sugars, their transport to the endoplasmic reticulum (ER)/Golgi, and in Golgi trafficking. Already, disorders in O-glycan biosynthesis form a substantial group of genetic diseases. In view of the number of genes involved in O-glycosylation processes and the increasing scientific interest in congenital disorders of glycosylation, it is expected that the number of identified diseases in this group will grow rapidly over the coming years.
Content: We first discuss the biosynthesis of protein O-glycans from their building blocks to their secretion from the Golgi. Subsequently, we review 24 different genetic disorders in O-glycosylation and 10 different genetic disorders that affect both N- and O-glycosylation. The key clinical, metabolic, chemical, diagnostic, and genetic features are described. Additionally, we describe methods that can be used in clinical laboratory screening for protein O-glycosylation biosynthesis defects and their pitfalls. Finally, we introduce existing methods that might be useful for unraveling O-glycosylation defects in the future.
The following articles in journals at HighWire Press have cited this article:
![]() |
C. A. McDonald, J. Y. Yang, V. Marathe, T.-Y. Yen, and B. A. Macher Combining Results from Lectin Affinity Chromatography and Glycocapture Approaches Substantially Improves the Coverage of the Glycoproteome Mol. Cell. Proteomics, February 1, 2009; 8(2): 287 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Laughlin, J. M. Baskin, S. L. Amacher, and C. R. Bertozzi In Vivo Imaging of Membrane-Associated Glycans in Developing Zebrafish Science, May 2, 2008; 320(5876): 664 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Velayos-Baeza, C. Toma, S. Paracchini, and A. P. Monaco The dyslexia-associated gene KIAA0319 encodes highly N- and O-glycosylated plasma membrane and secreted isoforms Hum. Mol. Genet., March 15, 2008; 17(6): 859 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Harper, A. C. Theos, K. E. Herman, D. Tenza, G. Raposo, and M. S. Marks Premelanosome Amyloid-like Fibrils Are Composed of Only Golgi-processed Forms of Pmel17 That Have Been Proteolytically Processed in Endosomes J. Biol. Chem., January 25, 2008; 283(4): 2307 - 2322. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Nijland, N. E. Schlabritz-Loutsevitch, G. B. Hubbard, P. W. Nathanielsz, and L. A. Cox Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway J. Physiol., March 15, 2007; 579(3): 643 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wopereis, S. Grunewald, K. M.L.C. Huijben, E. Morava, R. Mollicone, B. G.M. van Engelen, D. J. Lefeber, and R. A. Wevers Transferrin and Apolipoprotein C-III Isofocusing Are Complementary in the Diagnosis of N- and O-Glycan Biosynthesis Defects Clin. Chem., February 1, 2007; 53(2): 180 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. Cabrera, M. Amano, J. Mitoma, J. Chan, J. Said, M. Fukuda, and L. G. Baum Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death Blood, October 1, 2006; 108(7): 2399 - 2406. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |